-

Media Alert for Durnell Supreme Court Argument

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--On April 27th, Monsanto will argue before the U.S. Supreme Court in Durnell v. Monsanto, a Roundup case involving the application of federal preemption under FIFRA. A favorable ruling by the Supreme Court would provide essential regulatory clarity for companies who seek to bring currently approved and new products to market, addressing their ability to serve U.S. farmers and consumers. Former Solicitor General Paul Clement will argue the case for Monsanto.

More than 100 government, farm, business and non-profit groups – including the U.S. government --joined amici briefs in support of Monsanto’s position, urging the nation’s highest court to affirm Congress’ intent in including a “Uniformity” provision in FIFRA, and prevent a patchwork of state laws and labelling requirements which would threaten businesses, the economy, and farmers. Read more about the amici support for Monsanto here.

Monsanto also released the following statement regarding the oral argument in Durnell:

“Congress enacted FIFRA to establish a uniform, nationwide framework governing pesticide registration and labeling, and companies should not face liability under state law for complying with federally approved and science-based labeling requirements. Allowing such claims to proceed invites a patchwork of state standards that conflict with the uniformity objective Congress prescribed in law and creates regulatory uncertainties that impede the development of new agricultural innovations. The security and affordability of the nation’s food supply depend on farmers’ and manufacturers’ ability to rely on the science-based judgments of federal regulators. Clarification from the Court is essential to restore uniformity, certainty, and the rule of law.”

Contacts

Media Contact:
Brian Leake
(314) 370.3285

Monsanto


Release Versions

Contacts

Media Contact:
Brian Leake
(314) 370.3285

More News From Monsanto

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic R...

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new late-breaking analyses from its global, landmark Phase III OCEANIC-STROKE study of asundexian, an investigational oral Factor XIa inhibitor. In total, 13 abstracts will be presented, including four OCEANIC-STROKE sub-analyses. Additionally, Bayer will present nine real-world analyses examining stroke...

Post Durnell Argument Scenario Statements – Attributable to Monsanto

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--“We appreciate the Court’s careful consideration of FIFRA’s Uniformity language and how its federal preemption provision applies to state-based label warnings. “We believe the U.S. Government and the Company made persuasive arguments that state-based warning claims ‘in addition to or different from’ warning labels approved by EPA under FIFRA, as in Durnell, are preempted, and this is necessary to avoid a patchwork of 50 different warning labels....
Back to Newsroom